PCI Pharma Services Secures Strategic Investment to Expand Biotherapeutics Manufacturing Capabilities
核心洞察
PCI Pharma Services, a global CDMO specializing in biotherapies, received strategic investment co-led by Bain Capital (搜索) and existing investor Kohlberg (搜索), with support from Mubadala Investment Company (搜索).
The Philadelphia-based company has achieved over 450 successful product launches in the past five years and provides integrated end-to-end drug development and manufacturing services.
Investment will fund organic and inorganic growth initiatives, including expansion of sterile fill-finish capabilities for injectables and high-potency specialized manufacturing capacity.
PCI Pharma Services, a global contract development and manufacturing organization (CDMO) focused on innovative biotherapies, has secured a strategic investment co-led by Bain Capital (搜索) and existing lead investor Kohlberg (搜索), with significant reinvestment from Mubadala Investment Company (搜索). Partners Group (搜索) will continue supporting the company with a minority investment, though financial terms of the private transaction were not disclosed.
The Philadelphia-headquartered company provides clients with integrated end-to-end drug development, manufacturing and packaging capabilities designed to increase products' speed to market and opportunities for commercial success. PCI brings proven experience from more than 450 successful product launches over the last five years and over 50 years in pharmaceutical services.
Strategic Growth Focus
Kohlberg (搜索) and Mubadala, both initial investors in PCI since 2020, are partnering with Bain Capital (搜索) and PCI's management team, led by Chief Executive Officer Salim Haffar (搜索), to accelerate the company's growth trajectory and build upon its customer service experience. The collaboration aims to further enable PCI clients to bring life-changing biopharmaceutical therapies to market.
PCI will primarily focus on organic and inorganic growth initiatives, including expanding its suite of services and geographic reach. Leveraging global growth trends in biologics and specialized drug therapies, the company's future investments will include expansion of existing sterile fill-finish of injectables and high potent and specialized manufacturing capacity.
Manufacturing Infrastructure Investment
The strategic investment will enable PCI's significant continued investment in the United States, bolstering the nation's critical pharmaceutical manufacturing and supply chain infrastructure. This expansion comes as the biopharmaceutical industry faces increasing demand for specialized manufacturing capabilities, particularly in biologics and complex drug therapies.
"PCI has embarked on a purposeful journey to transform itself into a global CDMO by executing its successful growth strategy, providing industry-leading customer experience, and offering innovative and integrated supply chain solutions," said Haffar. "I am grateful for the ongoing support of our existing investors and enthusiastically welcome Bain Capital (搜索) and their deep, global healthcare and life science capabilities and expertise. Together we will grow PCI's commercial, clinical trial services, and development and manufacturing businesses to meet the future demands of our biopharmaceutical customers."
Industry Partnership Perspective
Devin O'Reilly (搜索), Partner at Bain Capital (搜索), emphasized the company's strong market position: "Anchored by an innovative, advanced platform that is consistently growing and setting new standards for the industry, PCI Pharma has built a well-deserved reputation as a differentiated partner to leading biopharma companies, ensuring critical therapies reach patients safely and efficiently. We look forward to working alongside Kohlberg (搜索) to build on this strong foundation."
The investment reflects growing investor confidence in the CDMO sector, particularly companies specializing in complex biotherapeutics manufacturing and development services that can help pharmaceutical companies navigate increasingly sophisticated drug development requirements.